Free Trial

Zevra Therapeutics (ZVRA) News Today

$4.56
-0.10 (-2.15%)
(As of 05/28/2024 ET)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Brokerages
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given an average rating of "Buy" by the six research firms that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages tha
Research Analysts Set Expectations for Zevra Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at William Blair decreased their Q2 2024 earnings estimates for Zevra Therapeutics in a report released on Monday, May 13th. William Blair analyst T. Lugo now forecasts that the company will earn ($0.46) per share for the quart
Zevra Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.44) Per Share, Roth Capital Forecasts (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Roth Capital boosted their Q2 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now anticipates that the company wi
FY2027 EPS Estimates for Zevra Therapeutics, Inc. Increased by Analyst (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital increased their FY2027 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now expects that the company will post ear
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Wednesday
Zevra Therapeutics (NASDAQ:ZVRA) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Analysts
Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brok
HC Wainwright Brokers Lift Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright raised their Q1 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now expects that the company will earn ($0
HC Wainwright Brokers Cut Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Zevra Therapeutics in a research note issued on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now expects that the company will post earnings per share of $0.
HC Wainwright Reiterates "Buy" Rating for Zevra Therapeutics (NASDAQ:ZVRA)
HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday.
Roth Capital Analysts Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital cut their Q1 2024 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Sunday, March 31st. Roth Capital analyst J. Aschoff now forecasts that the company will earn
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $18.00 at Maxim Group
Maxim Group lifted their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday.
Equities Analysts Set Expectations for Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at Roth Capital dropped their FY2028 EPS estimates for shares of Zevra Therapeutics in a research report issued on Sunday, March 31st. Roth Capital analyst J. Aschoff now forecasts that the company will earn $2.35 per share for the y
Zevra Therapeutics (NASDAQ:ZVRA) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research report on Monday.
William Blair Research Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair cut their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, March 27th. William Blair analyst T. Lugo now anticipates that the company will earn ($1.50) per
Zevra Therapeutics: Q4 Earnings Insights
Earnings Outlook For Zevra Therapeutics
KemPharm Inc (1GDA.DU)
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at William Blair
William Blair initiated coverage on Zevra Therapeutics in a report on Tuesday. They issued an "outperform" rating for the company.
Q4 2023 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Increased by Analyst
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright boosted their Q4 2023 earnings per share (EPS) estimates for Zevra Therapeutics in a report issued on Tuesday, March 5th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings
Roth Capital Comments on Zevra Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Roth Capital issued their FY2028 earnings per share (EPS) estimates for Zevra Therapeutics in a research report issued to clients and investors on Monday, March 4th. Roth Capital analyst J. Aschoff expects that the company will post earnings
Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

ZVRA Media Mentions By Week

ZVRA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ZVRA
News Sentiment

1.30

0.81

Average
Medical
News Sentiment

ZVRA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ZVRA Articles
This Week

3

2

ZVRA Articles
Average Week

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ZVRA) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners